Please use this identifier to cite or link to this item:
|Title:||Systemic AL amyloidosis: current approach and future direction||Authors:||Bou Zerdan, Maroun
Chaulagain, Chakra P
|Affiliations:||Faculty of Medicine||Keywords:||Amyloidosis
|Issue Date:||2023-04-26||Publisher:||National Library of Medicine||Part of:||Oncotarget||Volume:||14||Start page:||384||End page:||394||Abstract:||
Systemic Light chain (AL) amyloidosis is a monoclonal plasma cell proliferative disorder characterized by deposition of amyloidogenic monoclonal light chain fragments causing organ dysfunction. It is a fatal disease and if not diagnosed and treated early can lead to organ failure and potentially death. The renal system along with the cardiovascular system are the most common organs involved but other organs such as gut and liver can be involved as well. The initial evaluation of patients requires confirming the diagnosis with tissue biopsy and staining with Congo red followed by confirmatory typing with mass spectrometry of the Congo red positive tissue. Then establishing the extent of the organs involvement by various staging and biomarkers testing. The treatment options and the tolerability of therapy depend on the disease staging, frailty, and co-morbidities. The autologous hematopoietic cell transplantation (HCT) after high dose melphalan therapy is an effective strategy which is usually done after initial bortezomib induction therapy. Unfortunately, most systemic AL amyloidosis patients are not candidate for HCT due to frailty, old age, multi-organ involvement, renal and heart failure at the time of diagnosis. While it is widely accepted that the patients need to be treated until they achieve complete hematologic response, the maintenance therapy after HCT is not well established in AL amyloidosis. In this review, we report the literature on the latest treatment updates of AL amyloidosis and the ongoing clinical trials highlighting the future treatments.
|URI:||https://scholarhub.balamand.edu.lb/handle/uob/6835||DOI:||10.18632/oncotarget.28415||Open URL:||Link to full text||Type:||Journal Article|
|Appears in Collections:||Faculty of Medicine|
Show full item record
checked on Dec 2, 2023
checked on Nov 30, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.